Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 781 Shares of Company Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Brophy sold 781 shares of the stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $406.00, for a total transaction of $317,086.00. Following the completion of the transaction, the chief financial officer owned 50,856 shares of the company's stock, valued at $20,647,536. This represents a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

• 2 Biotech Stocks Shaping Up for Major Breakouts

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $510,755.32.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16.
• On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The shares were sold at an average price of $267.99, for a total transaction of $84,952.83.

Natera Price Performance

---

---

Shares of NASDAQ:NTRA opened at $436.00 on Friday. The stock has a market cap of $62.85 billion, a price-to-earnings ratio of -320.59 and a beta of 1.50. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41. The stock's 50 day moving average price is $375.27 and its 200 day moving average price is $265.54.

• 3 Under-the-Radar Healthcare Companies

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm's quarterly revenue was up 37.7% on a year-over-year basis. During the same period last year, the company posted ($0.74) EPS. On average, sell-side analysts expect that Natera, Inc. will post -1.14 EPS for the current year.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Institutional Investors Weigh In On Natera

• Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. BlackRock Inc. acquired a new position in shares of Natera in the 2nd quarter worth $2,962,770,000. K.J. Harrison & Partners Inc acquired a new stake in shares of Natera during the second quarter worth $5,117,000. Abbot Financial Management Inc. purchased a new stake in shares of Natera during the second quarter valued at $1,537,000. Eagle Health Investments LP purchased a new stake in shares of Natera during the second quarter valued at $4,302,000. Finally, BlueCrest Capital Management Ltd purchased a new stake in shares of Natera during the second quarter valued at $11,695,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research analyst reports. Leerink Partners set a $330.00 price objective on Natera in a report on Friday, August 7th. Rothschild & Co Redburn began coverage on Natera in a report on Tuesday, September 8th. They set a "buy" rating and a $385.00 target price on the stock. Wells Fargo & Company lifted their target price on Natera from $220.00 to $284.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Zacks Research cut shares of Natera from a "hold" rating to a "strong sell" rating in a research report on Friday, October 16th. Finally, Citigroup upped their price target on shares of Natera from $365.00 to $480.00 and gave the company a "buy" rating in a report on Tuesday, October 6th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $394.31.

Get Our Latest Stock Report on NTRA

About Natera

(Get Free Report)

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

Recommended Stories

• Five stocks we like better than Natera
• Phillips 66 Posts Strong Earnings But the Stock Doesn't Care
• NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
• GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
• Where's the Beef? Trian-Led Buyout Proposal Values Wendy's at $1.4B, But Is It Enough?

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].